Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Advanced Enzyme TechnologiesNSE:ADVENZYMES -0.95%88 Cyclically Adjusted PS Ratio is 5.11 as of Sep. 05, 2026, which is 18% below its 10-year median of 6.20. GuruFocus rates NSE:ADVENZYMES with a GF Score™ of 88/100 and a GF Value™ of ₹411.76 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,269 Chemicals companies, Advanced Enzyme Technologies ranks worse than 85.58% on this metric.
The historical rank and industry rank for Advanced Enzyme Technologies's Cyclically Adjusted PS Ratio or its related term are showing as below:
NSE:ADVENZYMES'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.83 Med: 6.2 Max: 10.62
Current: 5.11
During the past years, Advanced Enzyme Technologies's highest Cyclically Adjusted PS Ratio was 10.62. The lowest was 4.83. And the median was 6.20.
NSE:ADVENZYMES's Cyclically Adjusted PS Ratio is ranked worse than 85.58% of 1269
companies
in the Chemicals industry
Industry Median: 1.34
vs NSE:ADVENZYMES: 5.11
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Advanced Enzyme Technologies's adjusted revenue per share data for the three months ended in Jun. 2026 was ₹16.936. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹57.41 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Advanced Enzyme Technologies (NSE:ADVENZYMES) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Advanced Enzyme Technologies Cyclically Adjusted PS Ratio Related Terms
Advanced Enzyme Technologies Cyclically Adjusted PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Enzyme Technologies Cyclically Adjusted PS Ratio Chart
NSE:ADVENZYMES vs LIN, SHW, ECL: Cyclically Adjusted PS Ratio Comparison
For the Specialty Chemicals subindustry, Advanced Enzyme Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Enzyme Technologies Cyclically Adjusted PS Ratio vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Advanced Enzyme Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Advanced Enzyme Technologies's Cyclically Adjusted PS Ratio falls into.
Advanced Enzyme Technologies Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 5.11 mean?
Advanced Enzyme Technologies (NSE:ADVENZYMES) has a Cyclically Adjusted PS Ratio of 5.11 as of Sep. 05, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Advanced Enzyme Technologies and its competitors. This is 18% below median its historical median of 6.20. Over the past decade, Advanced Enzyme Technologies' Cyclically Adjusted PS Ratio has ranged from 4.83 to 10.62. According to the industry distribution chart, Advanced Enzyme Technologies ranks #1086 out of 1269 companies in the Chemicals industry, placing it in the top 85.6%.
Is Advanced Enzyme Technologies' Cyclically Adjusted PS Ratio too high?
Advanced Enzyme Technologies' current Cyclically Adjusted PS Ratio of 5.11 is 18% below median its 10-year median of 6.20. Over the past 10 years, this metric has ranged from a low of 4.83 to a high of 10.62. The Chemicals industry median Cyclically Adjusted PS Ratio is 1.34. Advanced Enzyme Technologies' value of 5.11 is 281.3% above this industry median. Based on the distribution chart, Advanced Enzyme Technologies ranks #1086 out of 1269 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, Advanced Enzyme Technologies has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Enzyme Technologies' Cyclically Adjusted PS Ratio compare to LIN and SHW?
According to the Chemicals industry distribution chart, Advanced Enzyme Technologies ranks #1086 out of 1269 companies for Cyclically Adjusted PS Ratio. This places Advanced Enzyme Technologies in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 1.34. Advanced Enzyme Technologies' value of 5.11 is 281.3% above this benchmark. Historically, Advanced Enzyme Technologies' own Cyclically Adjusted PS Ratio has ranged from 4.83 to 10.62 over the past decade. While the company's 10-year median is 6.20 vs. the industry median of 1.34, Advanced Enzyme Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Chemicals company?
The median Cyclically Adjusted PS Ratio among Chemicals companies is 1.34, based on 1,269 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Advanced Enzyme Technologies's current Cyclically Adjusted PS Ratio of 5.11 is 281.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Advanced Enzyme Technologies and its competitors. For the Chemicals industry, the median Cyclically Adjusted PS Ratio is 1.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Enzyme Technologies's current Cyclically Adjusted PS Ratio is 5.11, which is 18% below median its own 10-year median of 6.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Enzyme Technologies stock overvalued right now?
Based on GuruFocus' analysis, Advanced Enzyme Technologies (NSE:ADVENZYMES) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹411.76, compared to a current price of ₹293.20 — trading 28.8% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 5.11, which is 18% below median its 10-year median of 6.20 and 281.3% above the Chemicals industry median of 1.34. Advanced Enzyme Technologies' overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Advanced Enzyme Technologies (NSE:ADVENZYMES), the current Cyclically Adjusted PS Ratio is 5.11 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Advanced Enzyme Technologies (NSE:ADVENZYMES) Overvalued in 2026?
Based on GuruFocus' analysis, Advanced Enzyme Technologies stock appears to be undervalued.
The current stock price of ₹293.20 is trading 28.8% below its estimated GF Value™ of ₹411.76.
GuruFocus considers Advanced Enzyme Technologies to be Modestly Undervalued.
Key valuation signals for NSE:ADVENZYMES:
Cyclically Adjusted PS Ratio: 5.11 (18% below median its 10-year median of 6.20)
GF Value™: ₹411.76 vs. price of ₹293.20 (28.8% below fair value)
Industry Position: 281.3% above the Chemicals median (#1086 of 1269)
No single metric tells the full story. See the NSE:ADVENZYMES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Advanced Enzyme Technologies Ltd is an Indian company engaged in research activities to manufacture and sell enzymes. The company operates only in one business segment, viz., manufacturing and sales of enzymes. The company offers enzymes for human healthcare and nutrition, animal nutrition, food processing, and non-food processing. Some of the products offered by the company are serratiopeptidase, fungal lipase, papain, hemicellulose, and digegrain, among others. Geographically, the entity operates in India, Europe, the USA, Asia, and other countries, of which a majority of the revenue is derived from India.
88GF Score
Get the complete analysis for NSE:ADVENZYMES
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ADVENZYMES has been successfully added to your 
